Intelligence · Patents
Patents expiring in 2037
Annual patent cliff calendar for 2037 — US pharmaceutical patents by expiration date.
- Patents
- 1,615
Quick answer
1,615 indexed pharmaceutical patents have expiration dates in 2037. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 9844600
Injectable thermoresponsive polyelectrolytes
granted -
US 9845332
Neprilysin inhibitors
granted -
US 9846160
Ganglioside GD2 as a marker and target on cancer stem cells
granted -
US 9845350
Monoclonal antibodies that react with the capsule of bacillus anthracis
granted -
US 9845357
Integrin αvβ8 neutralizing antibody
granted -
US 9845512
Screening assay employing Dex and GDF8
granted -
US 9845346
Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
granted -
US 9845339
Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
granted -
US 9844655
Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
granted -
US 9845237
Supramolecular approach for preparation of size controllable nanoparticles
granted -
US 9844657
Compositions comprising nanostructures for cell, tissue and artificial organ growth, and methods for making and using same
granted -
US 9844611
Tissue-separating fatty acid adhesion barrier
granted -
US 9844656
Localization of agents at a target site with a composition and an energy source
granted -
US 9844598
Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors
granted -
US 9844568
Porous carbon particles for use in the treatment or prevention of liver disease
granted -
US 9844562
Polyvalent RNA-nanoparticle compositions
granted -
US 9844505
Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
granted -
US 9844495
Self-adhesive dental composite resin
granted -
US 9850542
Gene signature to predict homologous recombination (HR) deficient cancer
granted -
US 9849138
1,4-benzodiazepone-2,5-diones and related compounds with therapeutic properties
granted -
US 9849167
Compositions and methods for combination therapy with dengue virus and dendritic cells
granted -
US 9849100
Pharmaceutical compositions suitable for parenteral administration comprising aqueous suspensions of benzylamine derivatives having low solubilities
granted -
US 9850199
Metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide
granted -
US 9849191
Protein-polymer-drug conjugates
granted -
US 9850313
Cancer biomarkers and methods of use thereof
granted -
US 9850300
Compositions and methods relating to inhibiting cancer cell growth and/or proliferation
granted -
US 9850323
High concentration chitosan-nucleic acid polyplex compositions
granted -
US 9850277
Therapeutically active compositions and their methods of use
granted -
US 9850488
Complement component C5 iRNA compositions and methods of use thereof
granted -
US 9850497
Gene targeting methods and tools
granted -
US 9849171
PRRSV compositions
granted -
US 9849174
Methods and compositions related to immunogenic fibrils
granted -
US 9848853
System, method and devices for tissue-based diagnosis
granted -
US 9850244
Method for preparing Palbociclib
granted -
US 9850202
Ionizable cationic lipid for RNA delivery
granted -
US 9849109
Autotaxin inhibitors and uses thereof
granted -
US 9849133
Pharmaceutical formulations of xanthine or xanthine derivatives, and their use
granted -
US 9850468
Infectious hepatitis E virus genotype 3 recombinants
granted -
US 9850207
Substituted piperidines as soluble epdxide hydrolase inhibitors
granted -
US 2017369501
KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATIONS
granted -
US 9855312
GHRH agonists for the treatment of ischemic disorders
granted -
US 9855330
Granulysin in immunotherapy
granted -
US 9856204
Methods for inhibiting muscle atrophy
granted -
US 9855368
Bone morphogenic protein binding peptide
granted -
US 9856231
Tetrahydrothiophene-based GABA aminotransferase inactivators
granted -
US 9856206
Oligo-benzamide compounds and their use
granted -
US 9856238
1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders
granted -
US 9856279
Therapeutically active compositions and their methods of use
granted
Frequently asked questions
How many pharma patents expire in 2037?
1,615 published patents in our USPTO index have expiration dates falling in calendar year 2037.